



August 2008

Volume 13 · Numbers 15/16

pp. 637–730



Cover Story

The featured review in this issue of *Drug Discovery Today*, by Emma T. van der Westhuizen, Michelle L. Halls, Chrisan S. Samuel, Ross A.D. Bathgate, Elaine N. Unemori, Steven W. Sutton and Roger J. Summers, discusses relaxin family peptides, their receptors and physiological function. Targeting the relaxin system may be useful therapeutically for the treatment of a number of disorders, related to reproductive physiology, fibrosis, wound healing, infarction and congestive heart failure. Furthermore, conditions including stress, anxiety and obesity, may also potentially be addressed in a novel manner through the relaxin systems.

DRUG DISCOVERY TODAY

REVIEWS

KEYNOTE

640 Relaxin family peptide receptors – from orphans to therapeutic targets

Emma T. van der Westhuizen, Michelle L. Halls, Chrisan S. Samuel, Ross A.D. Bathgate, Elaine N. Unemori, Steven W. Sutton and Roger J. Summers

GENE TO SCREEN

652 Increasing the reliability of protein interactomes

Hon Nian Chua and Limsoon Wong

INFORMATICS

659 An early history of the molecular modeling industry

Allen B. Richon

665 Current status and future direction of the molecular modeling industry

Allen B. Richon

POST SCREEN

670 Orphan drug development across Europe: bottlenecks and opportunities

Harald E. Heemstra, Remco L.A. de Vreeh, Sonja van Weely, Hans A. Büller and Hubert G.M. Leufkens

677 Chemistry strategies in early drug discovery: an overview of recent trends

Matteo Colombo and Ilaria Peretto

685 Drug discovery in the extracellular matrix

Julie Huxley-Jones, Steven M. Foord and Michael R. Barnes

695 DARPinS: A new generation of protein therapeutics

Michael T. Stumpp, H. Kaspar Binz and Patrick Amstutz

702 Preclinical assessment of cardiac toxicity

Ralf Kettenhofen and Heribert Bohlen

708 Needed: system dynamics for the drug discovery process

Suzanne Sirois and L. Martin Cloutier

716 The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?

Boris Cvek and Zdenek Dvorak